Zambon Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Zambon's estimated annual revenue is currently $596.4M per year.(i)
  • Zambon's estimated revenue per employee is $201,000

Employee Data

  • Zambon has 2967 Employees.(i)
  • Zambon grew their employee count by 9% last year.

Zambon's People

NameTitleEmail/Phone
1
Chief Human Resources & Communications PharmaReveal Email/Phone
2
COO BreathReveal Email/Phone
3
CFOReveal Email/Phone
4
US Country Lead & VP CommercialReveal Email/Phone
5
Head Inhalation TechnologyReveal Email/Phone
6
Head Primary Care Business Unit at Zambon ItaliaReveal Email/Phone
7
Head Finance DepartmentReveal Email/Phone
8
Head Pharmaceutical Development & IndustrializationReveal Email/Phone
9
Head HRReveal Email/Phone
10
Head Application Competence CenterReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.7M31-14%N/AN/A
#2
$7.2M366%N/AN/A
#3
$17.7M8840%N/AN/A
#4
$28.7M1435%N/AN/A
#5
$1.4M7N/AN/AN/A
#6
$15.3M761%N/AN/A
#7
$596.4M29679%N/AN/A
#8
$5.4M27-10%N/AN/A
#9
$86.8M4327%N/AN/A
#10
$5M254%N/AN/A
Add Company

What Is Zambon?

Pharmaceutical, Respiratory, Pain, Woman Healthcare and Central Nervous System Zambon is a leading Italian family company that has operated for 109 years in the pharmaceutical and fine-chemical industry. Founded in Vicenza in 1906, today the Group operates directly in 73 countries with 15 operating subsidiaries in Europe, South America and Asia and more than 2,600 employees. Zambon has also facilities in Italy (Vicenza, Lonigo), Switzerland, France, Brazil and China. Zambon primarily operates in three strategic areas: respiratory, pain and women’s health. In these sectors, its business covers the entire value chain. The Group is particularly focusing on strengthening the respiratory area with the treatment of severe diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), with the recent acquisition of Profile Pharma from Philips. Zambon entered also into a new important therapeutic area, the Central Nervous System (CNS), with an innovative molecule for the treatment of Parkinson's disease. CNS and the Respiratory Business are the two main drivers of the company’s development strategy. Zambon is characterised by a strong identity and integrated organisational structure. Zambon Company is the industrial holding company, made up of Zach, Zambon Chemicals, which operates in the production of active ingredients and intermediates in three business areas: generic, custom and Zambon branded products. Other parts of the Group are: Zambon SpA global pharmaceutical business and Z-Cube, the Corporate Venture that supports the validation of drug delivery technologies and medical devices. ZCube has also developed a strong relationship with the International scientific community and has renovated a company history in the research and innovation field thanks to Open Zone, a scientific campus for the exchange of knowledge, research and innovation. In addition Zoé Foundation, was born with the aim of spreading a health’s culture enhancing a good communication both on the academic field and institutional field.

keywords:N/A

N/A

Total Funding

2967

Number of Employees

$596.4M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Zambon News

2022-04-17 - Zambon to present data on lung transplantation trends and ...

BOSTON, April 26, 2022 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve...

2022-04-17 - Fosfomycin Trometamol Market Size, Outlook And Forecast ...

Zambon, Northesat Pharm, Hunan Huana Pharmaceuticals, Xunda Pharma, FarmaSino Pharmaceutical, Guilin Hwasun.

2022-04-13 - Zambon Receives US FDA Breakthrough Therapy ...

Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB).

2019-07-25 - Zambon Acquires Breath Therapeutics, For Up To €500M

Zambon, an Italian multinational pharmaceutical company, acquired Breath Therapeutics, a biopharmaceutical company developing an innovative inhalation therapy for Bronchiolitis Obliterans Syndrome (BOS), for € 140m (up to total € 500m subject to regulatory and sales milestones). With the deal, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$955.6M2983N/AN/A
#2
$15M30939%N/A
#3
$922M31368%N/A
#4
$822.1M32857%$738.3M
#5
$75M33162%N/A